Written by: Hasan – Massive Bio
Massive Bio, a company specializing in artificial intelligence (AI) for cancer clinical trial enrollment, has unveiled a new portal called Patient Connect, aimed at improving access to clinical trials for cancer patients worldwide. The free platform enables patients to identify suitable clinical trials through an AI-powered matching system, enhancing the chances of finding personalized treatment options. By granting consent to share their medical records, patients can leverage the system to match with trials tailored to their diagnosis, treatment history, biomarkers, and location. The platform provides multilingual support and offers downloadable reports to help patients make well-informed decisions in collaboration with their physicians and caregivers.
Patient Connect has already enabled over 132,000 patients to access personalized trial matching results from nearly 16,000 cancer trials. The company’s AI-driven system has successfully linked patients to over 33,000 clinical trial sites, with a reported 12-fold increase in trial eligibility through its unique multi-trial matching approach. “Patient Connect redefines how patients engage with clinical trials, offering them a lifeline to new treatment possibilities and hope for better outcomes,” said Dr. Arturo Loaiza-Bonilla, Chief Medical Officer and Co-Founder of Massive Bio.
In addition to AI-driven insights, Massive Bio offers personalized support through its concierge services, which include guidance from patient relations coordinators, MDs, and oncology nurses. This team assists with logistical challenges, financial assistance needs, and the final steps of trial enrollment, ensuring a seamless transition for participants. For healthcare providers, the Massive Bio Clinical Network allows oncologists and hematologists to review pre-screening results and oversee the enrollment process. This dual engagement model uniquely combines patient and provider collaboration to streamline clinical trial participation.
Massive Bio’s platform is designed to address barriers to trial access, such as geographical or financial constraints, and align with the broader goal of equitable cancer care. The company is also a participant in the Cancer Moonshot White House initiative and a founding member of the CancerX public-private partnership. Since its founding in 2015, Massive Bio has worked with pharmaceutical companies, contract research organizations, and hospital networks to enhance clinical trial efficiency. The company operates globally, with over 100 employees across 17 countries.
For more details about Patient Connect or to learn about the Clinical Network for healthcare professionals, visit the Massive Bio website
Contact Information:
Massive Bio
Laisha Daley Hasan – SR. Marketing Manager
Phone: +1 844 627 7246
Stay informed with supply chain news on The Supply Chain Report. Free tools for international trade are at ADAMftd.com.
#CancerCare #ClinicalTrials #HealthTechnology #AIinHealthcare #PatientSupport
